CDXS - Codexis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100

Full Time Employees248

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen George Dilly MBBS, Ph.D.Pres, CEO & Director753.61kN/A1960
Mr. Kevin Norrett M.B.A., M.S.Chief Operating Officer507.28kN/A1973
Ms. Margaret Fitzgerald J.D.Chief Legal and Compliance Officer, Gen. Counsel & Sec.300.03kN/A1971
Mr. John J. NicolsDirector & Strategic Advisor1.29M2.96M1964
Mr. Sriram Ryali M.B.A.Chief Financial OfficerN/AN/A1982
Ms. Karen Frechou-ArmijoSr. VP & Head of HRN/AN/AN/A
Mr. Rob Wilson Ph.D.Sr. VP & GM of Performance EnzymesN/AN/AN/A
Dr. Stefan Lutz Ph.D.Sr. VP of ResearchN/AN/AN/A
Mr. Robert Sato M.B.A., Ph.D.Sr. VP of Pharmaceutical Devel., Quality & RegulatoryN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Corporate Governance

Codexis, Inc.’s ISS Governance QualityScore as of May 30, 2023 is 5. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.